Subscapularis Indocyanine Green Perfusion Pilot Study (ICG)
Shoulder Pain, Shoulder Arthritis, Shoulder Arthroplasty
About this trial
This is an interventional other trial for Shoulder Pain focused on measuring Orthopaedic, Shoulder, Joint Replacement, ICG, Indocyanine green
Eligibility Criteria
Inclusion Criteria:
Ages > 18 years old 18+ years old Meet clinical and radiographic parameters necessary to undergo shoulder arthroplasty Subscapularis tendon intact clinically on exam or via advanced imaging Subject has the ability to have their shoulder arthroplasty completed using either the tenotomy or peel technique.
Exclusion Criteria:
Inability of patient to provide informed consent Iodine allergy Subscapularis tendon tear or concern for tear Incarceration Pregnant women via verbal indication Ages <18 years old Prior deltopectoral approach to the ipsilateral shoulder
Sites / Locations
- Dartmouth Hitchcock Medical Center
Arms of the Study
Arm 1
Experimental
patients requiring a shoulder arthroplasty
Patients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an FDA approved imaging system.